Infinity minus one: shares plummet as spiky saridegib fails in pancreatic cancer
This article was originally published in Scrip
Infinity Pharmaceuticals has halted a Phase II trial of one of its key clinical programmes – for its experimental pancreatic cancer drug saridegib (also known as IPI-926), a Hedgehog pathway inhibitor, being studied in combination with gemcitabine. An interim analysis showed that there was better survival in the control arm of the trial than in the saridegib treatment arm. Infinity's shares dropped $3.97, or 40%, to close at $5.97 on 27 January.
You may also be interested in...
Infinity's hopes for accelerated approval of duvelisib based on the DYNAMO study have been dashed, so as the company plots a new strategy for the PI3K inhibitor – with or without its partner AbbVie – it has cut discovery research operations, including 46 jobs.
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.